Selected Non-Hodgkin's Lymphoma abstracts from the American Society of Hematology (ASH) 2004 convention

http://www.abstracts2view.com/hem_sandiego2004/

List compiled by
 Greg Dafoe

See also the new 2007 ASH abstracts

Return the the NHL Cyberfamily home page

CONTENTS

  1. Autologous Transplantation in Lymphoma

  2. Graft Versus Host Disease

  3. Lymphoma Therapy with Rituxan

  4. Relapse, Immune responses and Immunotherapy after transplantation

  5. Diffuse Large B Cell Lymphoma - Molecular heterogeneity and Pathogenesis

  6. Late effects after Transplantation

  7. Therapy of Aggressive Lymphomas and Radioimmunotherapy

  8. Allogeneic HCT Complications and Engraftment

  9. Late Effects, Chronic GVHD and Second Cancers after Transplantation

  10. New Therapies for Non-Hodgkin's Lymphoma

  11. Radioimmunotherapy - Non Hodgkin's Lymphoma and T-cell Lymphoma

  12. Chemotherapy and Rituximab combinations for B-Cell Non-Hodgkin's Lymphoma

  13. Clincial trials and drug approval

  14. Graft Versus Host Disease

  15. Follicular Lymphoma Therapy

  16. Lymphoma Chemotherapy

  17. Allogeneic Mismatched and Unrelated Transplantation

  18. Clinical results of Autologous Transplantation

  19. Lymphoma Biology - Prognostic markers

  20. Lymphoma Therapy - New Biologic Agents

  21. Lymphomas - Chemotherapy and Management of Treatment Complications

  22. Lymphoma - Therapy with Biologic Agents

  23. Reduced Intensity Conditioning

  24. Strategies to Improve Allogeneic Mismatched and Unrelated Transplantation

 

Autologous Transplantation in Lymphoma

[890] Autologous Transplant Event-Free Survival (EFS) Following Failure of CHOP-Rituximab (CHOP-R) for Diffuse Large B-Cell Lymphoma (DLBCL) Is the Same as the EFS Following Failure of CHOP Alone.

891] Rituximab-Supplemented High-Dose Sequential (HDS) Chemotherapy with Autograft Is Highly Effective in High-Risk (aaIPI 2-3) Diffuse Large B-Cell Lymphoma: Results of a Prospective Multicenter Study on 91 Consecutive Patients Treated at Diagnosis.

 [892] Increasing the Number of Apheresis Collections Increases Lymphocyte Collection and Affects Survival after Autologous Stem Cell Transplantation for Non-Hodgkin Lymphoma.

[893] Ann Arbor Stage Is the Most Important Predictor of Survival for Refractory and Relapsed HIV-Associated Lymphoma Enrolled in a Program of High Dose Therapy and Autologous Peripheral Blood Stem Cell Transplantation.

 [894] Autologous vs Allogeneic Cell Transplantation for Mantle Cell Lymphoma (MCL): Outcomes over a 10-Year Period at City of Hope.

 [895] Intense Immunochemotherapy (IC) and Autologous Stem Cell Transplant (ASCT) for Untreated Patients (pts) with Mantle Cell Lymphoma (MCL): CALGB 59909. A Preliminary Report.

 [896] High Dose Therapy with Autologous Blood Stem Cell Transplantation (ASCT) for Follicular Lymphoma: Long-Term Outcome According to Histologic Grade.

 [897] Dose Finding Trial of Yttrium 90 (90Y) Ibritumomab Tiuxetan with Autologous Stem Cell Transplantation (ASCT) in Patients with Relapsed or Refractory B-Cell Non-Hodgkin’s Lymphoma (NHL).

 [898] Risk Adapted Dose Intensive DICEP Salvage Chemotherapy Prior to Autologous Stem Cell Transplantation Yields Successful Outcomes in Chemotherapy Refractory Lymphoma.

 [899] Safety and Efficacy of CBV Followed by Autologous PBSC Transplant in Children with Lymphoma after Failed Induction or First Relapse - A Children's Oncology Group Study. S

 [900] Hematopoietic Stem Cell Transplant (HSCT) as Primary Treatment for T-Cell Lymphobastic Lymphoma (T-LBL): An Intention to Treat Analysis.

 [901] Outcomes of Autologous and Allogeneic BMT for Mantle Cell Lymphoma.

 [902] Front-Line High-Dose Chemotherapy (HDT) Combined with Rituximab for Adults with Aggressive Large B-Cell Lymphoma (DLBCL): GOELAMS 074 Trial.

 [903] Long-Term Outcome of High-Dose Sequential Chemotherapy with Autografting (i-HDS) in Follicular Lymphoma at Diagnosis: An Update of the Prospective Multicenter Consecutive Trial of the "Gruppo Italiano Trapianto Di Midollo Osseo" (GITMO).

 [904] Autologous Stem Cell Transplantation as First Line Therapy in Peripheral T Cell Lymphomas. Update of a Prospective Multicenter Study.

 [905] GDP (Gemcitabine, Dexamethasone, Cisplatin) Salvage Therapy Results in Superior Progression Free Survival Compared to Mini-Beam Prior to Autologous Stem Cell Transplantation for Relapsed or Refractory Hodgkin's Lymphoma.

 [906] Post-Transplant Positron Emission Tomography Using Fluorine 18-Fluoro-Deoxyglucose ([18F]FDG-PET) Correlates with Outcome in Patients with Aggressive Non-Hodgkin’s Lymphoma Undergoing High Dose Chemotherapy Followed by Autologous Stem-Cell Transplantation (HDC/ASCT).

 [907] Routine Imaging Identifies a Group of Patients with More Favorable Aggressive NHL at Relapse: A Retrospective Study of a Uniformly Treated Patient Population.

 [908] Autologous Transplantation for Diffuse Large B Cell Lymphoma: Pre-Transplant Hypogammaglobulinemia Is a Predictor for Early Toxicities.

 [909] Long-Term Follow-Up of High-Dose Chemotherapy Followed by Autologous Stem Cell Transplantation in Peripheral T-Cell Lymphomas at Diagnosis.

 [910] In Vivo Purge with Rituximab before Harvest Does Not Alter the Graft nor the Hematologic Recovery after Transplant.

 [911] High Dose Thiotepa, Busulfan, Cyclophosphamide (TBC) and Autologous Hematopoietic Stem Cell Transplantation (ASCT) without Whole Brain Radiotherapy (WBRT) for Primary Central Nervous System Lymphoma (PCNSL).

 [912] Lower Relapse Incidence after Non-Cryopreserved Autologous Bone Marrow Transplantation Compared to Peripheral Blood Stem Cell Transplantation for High-Risk Hodgkin’s Lymphoma.

 [913] Dose Dense, High Intensity Induction Therapy Followed by Early High Dose Chemotherapy (HDT) and Autologous Hematopoietic Stem Cell Transplantation(AHSCT) for Mantle Cell Lymphoma (MCL).

 [914] High Dose Therapy / ASCT with Rituximab for In-Vivo Purging and Post-ASCT Consolidation in Relapsed Follicular Lymphoma Achieves Prolonged Clinical and Molecular Remissions.

 [915] A Prospective Phase II Comparison of Stem Cell Source Using Rituximab, Ifosfamide, Carboplatin, Etoposide (RICE) Re−Induction, Then High Dose Fludarabine, Busulfan (FluBu) and Autologous (ASCT) or Allogeneic (AlloSCT) Hematopoietic Blood Stem Cell Transplantation for Mantle Cell (MCL) and Relapsed Low-Grade B-Cell Non-Hodgkin's Lymphoma (NHL).

 [916] Tandem Autologous Stem Cell Transplantation Following High Dose Chemotherapy for Transformed Low Grade and Refractory High Grade Lymphoma.

 [917] Time-Dependent Effect of Non-Hodgkin’s Lymphoma Grade on Disease Free Survival (DSF) of Relapsed/Refractory Patients Treated with High-Dose Chemotherapy (HDC) Plus Autologous Hematopoietic Stem Cell Transplant (AHSCT).

 [918] Prospective Study of Immunomodulation with GM-CSF, IL-2, and Rituximab Following Autologous Stem Cell Transplant (SCT) in Patients with Relapsed Lymphomas.

 [919] Comparison of the Sequential High-Dose Chemotherapy Followed by Autologous Stem Cell Support with and without Rituximab in Relapsed and Refractory Aggressive Non-Hodgkin’s Lymphoma.

 [920] High-Dose Chemotherapy with Autologous Stem Cell Support Is Not Superior to Conventional-Dose Chemotherapy in the First-Line Treatment of Aggressive Non-Hodgkin Lymphoma – Results of a Comprehensive Meta-Analysis. 

[7] Early Consolidation with Myeloablative Radiochemotherapy Followed by Autologous Stem Cell Transplantation in First Remission Significantly Prolongs Progression-Free Survival in Mantle Cell Lymphoma – Long Term Follow up of a Prospective Randomized Trial of the European MCL Network. S

[8] Nordic Mantle Cell Lymphoma (MCL) Project: Prolonged Follow-Up of 86 Patients Treated with BEAM/BEAC + PBSCT Confirms That Addition of High-Dose Ara-C and Rituximab to CHOP Induction + In-Vivo Purging with Rituximab Increases Clinical and Molecular Response Rates, PCR-Neg. Grafts, Failure-Free, Relapse-Free and Overall Survival. 

[9] Early Dose Intensity Is Critical in Patients with Aggressive Lymphoma: A Randomized Study Comparing Identical Doses of Cyclophosphamide, Adriamycin, Vincristine, Etoposide, and Prednisolone Given as 4 or 6 Cycles Followed by Repetitive Transplantation of Stem Cells (Mega-CHOEP). 

[10] The Importance of Molecular Phenotype in Predicting Overall Survival in Patients with Relapsed or Primary Refractory DLBCL Treated with Second-Line Chemotherapy and ASCT. 

[11] Patients with Lymphoplasmacytic Lymphoma Can Be Salvaged with Autologous Stem Cell Transplantation, Irrespectively of the Number of Previous Treatment Lines. Analysis of 146 Cases from the European Bone Marrow Transplant Registry (EBMT). 

[12] The Follicular Lymphoma International Prognostic Index (FLIPI) as Part of a Proposed Prognostic Model for Follicular Lymphoma Patients Undergoing Autologous Hematopoietic Stem Cell Transplantation (ASCT).

Graft Versus Host Disease

[1226] Pretransplant Recipient Blood CD14+ preDC Levels Correlate with Increased Acute GVHD after Allogeneic PBSC Transplantation.

[1227] Sirolimus and Tacrolimus as Graft-vs.-Host Disease Prophylaxis in Allogeneic Stem Cell Transplantation: The Dana-Farber Cancer Institute Experience.

[1228] Keratinocyte Growth Factor Factor (Palifermin) in Combination with Tacrolimus and Methotrexate for the Prevention of Acute Graft-vs-Host Disease (aGVHD) in Patients at High Risk of aGVHD.

[1229] Human Memory T Cells Proliferate but Do Not Elicit Cytotoxicity in Response to Alloantigens.

[1230] A Multi-Institutional Study of Extracorporeal Photoimmune Therapy with UVADEX® for the Prevention of Acute GVHD in Patients Undergoing Standard Myeloablative Conditioning and Allogeneic Hematopoietic Stem Cell Transplantation.

[1233] Petreatment with Rituximab Reduces the Incidence of Chronic Graft-Versus-Host Disease after Allogeneic Stem Cell Transplantation in Patients with B Cell Lymphoma.

[1234] Long Term Infectious Complications Following Reduced Intensity Conditioning (RIC)Allogeneic HLA-Identical Sibling Transplantation (allo-SCT).

[1236] Evaluation of Three Different Cyclosporine-Based Graft Versus Host Disease (GVHD) Prophylaxis Regimens Following Nonmyeloablative Hematopoietic Stem Cell Transplantation (NST).

[1237] Steroid Refractory GVHD of the Gut Can Be Treated Effectively with Daclizumab and Sirolimus.

[1238] Association of Skin and Blood Dendritic Cells with Acute Graft Versus Host Disease after Human Haematopoetic Cell Transplantation.

[1239] Improved Immune Reconstitution with Low Incidence of Severe Graft-Versus-Host Disease after Transplantation of CD34+ or CD133+ Enriched Stem Cells with Add-Back of Ten Million T-Cells Per Kg.

[1240] Naive and Non Naive CD4+ and CD8+ T Cell Subsets Distribution in Blood and Marrow Grafts and Their Impact on Patients’ Outcome after Allogeneic Stem Cell Transplantation.

[1241] Fludarabine and Busulfan-Based Reduced Intensity Conditioning (RIC) Allogeneic HLA-Identical Transplantation (allo-SCT) with or without Anti-Thymocyte Globulin (ATG): Comparison between Two Prospective Studies in Patients with Myeloid Malignancies.

[1244] Excellent Long-Term Survival of Patients with Steroid-Refractory and Steroid-Dependent Acute Graft-Versus-Host Disease after Extracorporeal Photochemotherapy.

[1246] Grade 2-4 Acute Graft-Versus-Host Disease and Extensive Chronic Graft-Versus-Host Disease Are Associated with Significantly Decreased Survival Following Reduced Intensity Allogeneic Stem Cell Transplantation.

[1247] Prognostic Factors Identifiable at the Time of Onset of Acute Graft-Versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation.

[1253] Therapeutic Plasma Levels of OKT3 Muromonab Are Effective as Second-Line and Subsequent Treatment in Recipients of Stem Cell Allografts with Steroid-Resistant Acute Graft-Versus-Host Disease.

[1254] Acute Graft Versus Host Disease after Nonmyeloablative Allogeneic Stem Cell Transplantation with Low-Dose TBI, Fludarabine and Antithymocyte Globulin (ATG).

[1255] Treatment of Steroid-Refractory Acute Graft Versus Host Disease with Low Dose Combination Monoclonal Antibody Therapy: A Pilot Study.

[1255.5] Transplantation with Higher Dose of Natural Killer Cells Associated with Better Outcomes in Terms of Non-Relapse Mortality and Infectious Events after Allogeneic Peripheral Blood Stem Cell Transplantation from HLA-Matched Sibling Donors.

Lymphoma Therapy with Rituxan

[1383] Long Term Results of the GELA Study, R-CHOP vs. CHOP in Elderly Patients with Diffuse Large B-Cell Lymphoma. S

[1384] Rituximab, Bevacizumab (Avastin) and CHOP (RA-CHOP) for Patients with Diffuse Large B-Cell Lymphoma (DLBCL).

[1385] Phase I/II Study of Bortezomib Alone and Bortezomib with Dose-Adjusted EPOCH Chemotherapy in Relapsed or Refractory Aggressive B-Cell Lymphoma.

[1386] Phase II Clinical Study of Bortezomib (VELCADE®) in Patients (pts) with Relapsed / Refractory Non-Hodgkin's Lymphoma (NHL) and Hodgkin's Disease (HD).

[1387] Sensitivity, Schedule-Dependence and Molecular Effects of the Proteasome Inhibitor Bortezomib in Non-Hodgkin’s Lymphoma Cells.

[1388] Phase II Study of Modified Hyper-CVAD with Rituximab Maintenance for Previously Untreated Mantle Cell Lymphoma: A Wisconsin Oncology Network Study.

[1389] Rituximab/Chemotherapy Induction Treatment Followed by High-Dose Therapy and Autologous Transplantation in Patients with Mantle Cell Lymphoma.

[1390] Rituximab and Stem Cell Transplantation Produces Durable Remissions in Mantle Cell Lymphoma.

[1391] Evolution of Rituximab as “Standard” Therapy in Patients (pts) with Newly Diagnosed Follicular (FL), Mantle Cell (MCL), and Diffuse Large B Cell (DLCL) Non-Hodgkin's Lymphoma (NHL) in 5 United States Comprehensive Cancer Centers: An Analysis from the National Comprehensive Cancer Network (NCCN) NHL Outcomes Project.

[1392] Manteinance Treatment with Interferon (IFN) Is Not Necessary to Achieve Prolonged Progression Free Survival (PFS) in Patients with Indolent Non Hodgkin´s Lymphoma (NHL). Results from a Prospective Randomized Trial on 165 Patients.

[1393] Long-Term Complete Molecular Remissions in Untreated Symptomatic Follicular Lymphoma Treated with Rituximab as Single Agent and in Combination with Interferon-alpha-2a: Analysis of Minimal Residual Disease in the Randomized Phase II Study M39035.

[1394] Myelodysplasia and Acute Myeloid Leukemia Following Therapy for Indolent Lymphoma with Fludarabine, Mitoxantrone, Dexamethasone (FND) Plus Rituximab and Interferon Alfa.

[1395] The Use of Gene-Expression Profiling to Predict Outcome of Follicular Lymphoma Patients Treated with Rituximab and Chemotherapy. Session Type:

[1396] Phase I/II Study of Rituxan (R) in Combination with Doxil (D) in Patients (pts) with Relapsing or Refractory B-Cell Lymphoma: Promising Early Results.

[1397] Lack of Increased Clinical Efficacy When Interleukin-12 Is Added to Rituximab in B-Cell Lymphoma Patients Is Related to Inadequate Delivery of the Cytokine to the Sites of Lymphoma.

[1398] In Vivo Downregulation of Bcl-2 by G3139 (G) Enhances Rituximab (R) Anti-Tumor Activity: Effect of Sequential Versus Concurrent G3139 Administration on Survival in a Lymphoma-Bearing SCID Mouse Model.

[1399] A Small-Molecule Bcl-2 Inhibitor Amplifies NKT-Cell Killing of U937 Lymphoma Cells.

[1400] HuMax-CD20 Fully Human Monoclonal Antibody in Follicular Lymphoma. First Human Exposure: Early Results of an Ongoing Phase I/II Trial.

[1401] Anti-CD20 Antibody Rituximab and Anti-CD23 Antibody IDEC-152 Induce Apoptosis of Malignant B-Cells in Combination with Chemical Antagonists of XIAP.

[1402] Treatment with an Anti-C3b/iC3b Monoclonal Antibody as an Adjuvant to Rituximab Enhances the Killing of Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia Cells.

[1403] Phase 1 Study of Talabostat and Rituximab in Patients with Indolent Non-Hodgkin's Lymphoma with Primary Resistance to or Progression Following Rituximab.

[1404] Mechanisms of IL-21 Enhancement of Rituximab Efficacy in a Lymphoma Xenograft Model.

[1405] Improving the Efficacy of Rituxan by Rational Protein Engineering.

[1406] First-Line Treatment with Rituximab Improves Survival of Patients with Post-Transplant Lymphoproliferative Disease (PTLD).

[1407] Rapid Infusion Rituximab in Combination with Steroid Containing Chemotherapy Can Be Given Safely and Substantially Reduces Resource Utilization.

[1408] Maintenance Rituximab after Autologous Stem Cell Transplant for High-Risk B-Cell Lymphoma Induces Prolonged and Severe Hypogammaglobulinemia.

[1409] Characterization of Cellular Immune Responses to a Recombinant Idiotype Vaccine by ELISPOT and Identification of MHC Class I-Restricted T Cell Epitopes by Peptide Mapping.

[1410] A Novel Method for Producing Custom-Made Idiotype Vaccines for Lymphoma Immunotherapy Using a Cell-Free Expression System.

[1411] A New Vaccine Paradigm To Break Tolerance with Potential Applications for the Immunotherapy of B Cell Lymphoma.

Relapse, Immune responses and Immunotherapy after transplantation

[1638] Impact of Prior Pregnancy on Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation.

[1639] Incompatibilities of HA-1 and CD62L Polymorphic Adhesion Molecule Induce Graft-Versus-Leukemia Effect Rather Than GVHD Resulting in Long-Term Survival in HLA Identical Myeloablative Stem Cell Transplantation.

[1640] Enhancing Graft-vs-Tumor (GVT) Activity of Donor Leukocyte Infusions by Ex-Vivo Expansion and Activation with CD3/CD28 Co-Stimulation.

[1641] Comparison of Conventional Versus Lineage-Specific Chimerism Analysis for Detection of Minimal Residual Disease or Relapse in Myeloid Malignancies after Myeloablative Allogeneic Hematopoietic Cell Transplantation with Respect to Clinical Follow-Up.

[1642] Donor Lymphocyte Infusions to Prevent Relapse in Acute Leukemias after Allogenic Stem Cell Transplantation.

[1643] Immunotherapy and Chemotherapy Can Result in Long-Term Survival for Patients with Recurrent or Progressive Non-Hodgkin’s Lymphoma after Reduced-Intensity Allogeneic Stem Cell Transplantation.

[1646] Low Dose Thalidomide and Donor Lymphocyte Infusion as Adoptive Immunotherapy after Allogeneic Stem Cell Transplantation in Patients with Multiple Myeloma.

[1647] Serum Level of Interleukin-10 Correlates Well with the Activity of Chronic Graft-Versus-Host Disease and the Responsiveness to Corticosteroid Treatment.

[1652] Eradication of Minimal Residual Disease during Treatment of Mantle Cell Lymphoma: CALGB 59909.

[1653] High Response Rate to DLI Based Strategies for the Treatment of Refractory Disease/ Relapse Following Allogeneic HSCT for Lymphoproliferative Disease.

Diffuse Large B Cell Lymphoma - Molecular heterogeneity and Pathogenesis

[25] Molecular Profiling of Diffuse Large B-Cell Lymphoma Identifies Robust Subtypes Including One Characterized by Host Inflammatory Response.

[26] Mechanisms of Bcl-2 Protein Expression in Diffuse Large B-Cell Lymphoma (DLBCL).

[27] De Novo t(14;18) Diffuse Large B-Cell Lymphoma Is Characterized by a Germinal Center B Cell-Like Phenotype and Acquisition of Glycosylation Sites by Somatic Mutation in Immunoglobulin VH Genes.

[28] A Novel NF-kB:NFAT Enhanceosome Synergistically Regulate CD154 Gene in Aggressive B Cell Lymphomas.

[29] Activation of Classical and Alternative Nuclear Factor-kappaB (NF-kB) Pathways in Diffuse Large B-Cell Lymphomas.

[30] Clinical Outcome Correlations of Genomic Gains and Losses in Diffuse Large B-Cell Lymphoma by Array-CGH

Late effects after Transplantation

[55] Is the Risk of Breast Cancer Increased after Hematopoietic Cell Transplantation?

[56] Late Mortality Following Allogeneic Stem Cell Transplantation Is Closely Associated with Chronic Graft Versus Host Disease but Not with Donor Type.

[57] Treatment of Osteopenia/Osteoporosis in Pediatric Hematopoietic Cell Transplantation.

[58] Pregnancy Outcomes after Hematopoietic Cell Transplantation (HCT): A Report from the BMT Survivor Study.

[59] Functional Limitations, Physical Disability and Social Competence among HCT Survivors Transplanted during Childhood or Adolescence: A Report from the Bone Marrow Transplant Survivor Study.

[60] Secondary Malignancies after Autologous Stem Cell Transplantation for Hodgkin´s Lymphoma: Incidence and Analysis of Risk Factors

Therapy of Aggressive Lymphomas and Radioimmunotherapy

[127] Rituximab-CHOP Versus CHOP with or without Maintenance Rituximab in Patients 60 Years of Age or Older with Diffuse Large B-Cell Lymphoma (DLBCL): An Update.

[128] Rituximab Plus Hypercvad (R-HCVAD) Alternating with Rituximab Plus High-Dose Methotrexate-Cytarabine (R-M/A) in Untreated Mantle Cell Lymphoma (MCL): Prolonged Follow-Up Confirms High Rates of Failure-Free Survival (FFS) and Overall Survival (OS).

[129] Anti-Tumor Activity of Single-Agent CCI-779 for Relapsed Mantle Cell Lymphoma: A Phase II Trial in the North Central Cancer Treatment Group.

[130] Yttrium-90 Ibritumomab Tiuxetan (Zevalin) for Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Not Appropriate for Autologous Stem Cell Transplantation: Results of an Open-Label Phase II Trial.

[131] Phase I/II Study of Fractionated Radioimmunotherapy (RIT) in Relapsed Low Grade Non-Hodgkin’s Lymphoma (NHL).

[132] Impact of Course of Therapy on Response Rate and Duration with the Bexxar® Therapeutic Regimen (Tositumomab and Iodine I 131 Tositumomab) and with Chemotherapy

Allogeneic HCT Complications and Engraftment

[1818] Unrelated Donor Peripheral Blood Stem Cell (PBSC) Transplantation Using Nonmyeloablative Conditioning and Mycophenolate Mofetil (MMF) TID Results in High Engraftment Rates.

[1821] Kinetics of Chimerism Conversion to Total Donor Profile: Impact on Transplant Outcome after Reduced Intensity Conditioning Allogeneic Transplantation.

[1822] A Phase II Trial of Busulfan, Melphalan, and Fludarabine Followed by Allogeneic T-Cell Depleted Hematopoietic Stem Cell Transplants from HLA-Identical, or HLA-Non Identical Related or Unrelated Donors for the Treatment of Advanced Hematopoietic Malignancies.

[1825] Fludarabine Is Superior to Cladribine When Added to Busulfan and Low Dose TBI as Reduced Intensity Conditioning for Allogeneic Hematopoietic Cell Transplantation (HCT): A Prospective Randomized Trial.

[1827] Total Body Irradiation (TBI), Fludarabine (F), Melphalan (M) and Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) for Advanced Pediatric Hematologic Malignancies.

[1828] Radiation Dose Determines Degree of Donor Chimerism after Nonmyeloablative Hematopoietic Cell Transplantation.

[1829] Immunoablative Chemotherapy before Reduced-Intensity Allogeneic Stem Cell Transplantation: A Strategy To Provide Disease Control and To Enhance Early Graft-Versus-Lymphoma Effects.

[1831] Invasive Pulmonary Aspergillosis Is Not a Contraindication to Reduced-Intensity Conditioned Allogeneic Haematopoietic Stem Cell Transplantation (RIC allo-HSCT).

[1832] Cytokine Production and Proliferation in Mixed Lymphocyte Culture (MLC) May Predict Donor Engraftment in Adult Recipients of Multiple Umbilical Cord Blood (UCB) Unit Transplantation.

[1833] First Report of a Prospective Randomised Controlled Trial of Recombinant Human Erythropoietin after Allogeneic Blood Stem Cell Transplantation.

[1836] Prediction and Prevention of Transplant Related Mortality from Pulmonary Causes Following Total Body Irradiation and Allogeneic Stem Cell Transplantation.

[1839] Clonal Gammopathies, Immune Cytopenias and Autoimmune Thyroid Dysfunction Following Alemtuzumab Containing Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation.

[1841] Frequent but Reversible and Manageable Cardiac Complications after Successful Haploidentical HLA-Mismatched Hematopoietic Stem Cell Transplantation (HSCT) without Ex Vivo Graft Manipulation.

[1842] Late Development of Acute Myeloid Leukemia in Two Peripheral Blood Stem Cell Donors Mobilized with G-CSF.

[1843] Peritransplant Use of Ultraviolet-B (UVB) Phototherapy Is Detrimental to Outcome of Allogeneic Stem Cell Transplantation.

[1844] Negative Impact of Pre-Transplant Anemia on Long-Term Outcome after Allogeneic Hematopoietic Stem Cell Transplantation

Late Effects, Chronic GVHD and Second Cancers after Transplantation

[2247] Evidence of Donor Derived Malignancies Following Hematopoietic Stem Cell Transplantation.

[2248] Incidence and Risk-Factors of Secondary Myelodysplastic Syndrome/Acute Leukemia Following High-Dose Chemotherapy and Autograft: A Long-Term Analysis on 307 Lymphoma Patients.

[2249] Pentostatin: Efficacy in Refractory Chronic GVHD in Children.

[2250] Adult Recipients of Matched Related Donor Blood Cell Transplants (BCT) Given Pretransplant Low-Dose Antithymocyte Globulin (ATG) Have Less Chronic Graft-Versus-Host Disease (cGVHD) and Transplant-Related Mortality (TRM): A Matched Pair Analysis.

[2251] Rituximab Therapy for Steroid-Refractory Chronic GVHD: Safety and Efficacy Analysis.

[2252] The Relationship between Host Antigen-Presenting Cells and Graft-Versus-Host Responses Following Human Nonmyeloablative Transplantation.

[2253] Pamidronate Therapy for One Year after Allogeneic Bone Marrow Transplantation (AlloBMT) Reduces Bone Loss from the Lumbar Spine, Femoral Neck and Total Hip.

[2254] Health-Related Quality of Life (HRQL) in Adult Long-Term Hematopoietic Cell Transplant (HCT) Survivors: A Report from the Bone Marrow Transplant Survivor Study.

[2256] Impaired Platelet Production and Autoantibody-Mediated Platelet Destruction Are Two Major Causes for Prolonged Thrombocytopenia after Allogeneic HSCT.

[2257] The Importance of Age, Fludarabine and Total Body Irradiation in the Incidence and Severity of Chronic Renal Failure Following Allogeneic Hematopoietic Stem Cell Transplantation.

[2260] Reduced Intensity Allogeneic Stem Cell Transplantation for Mantle Cell Lymphoma Is Associated with Substantial Late Transplant Related Mortality and a Poor Outcome in Patients with Chemoresistant Disease.

[2261] The Role of PET Scanning in Directing Immune Manipulations Following Reduced Intensity Transplants in Adults with Lymphoid Malignancies.

[2263] Recipient Epstein Barr Virus (EBV) Seropositivity with IgG Antibodies Against Early Antigens (EA) Could Be a Predictive Marker for the Early Onset of Post Transplant Lymphoproliferative Disorders (PTLDs) after Allogeneic Non T Depleted Stem Cell Transplantation.

New Therapies for Non-Hodgkin's Lymphoma

[2480] SDX-105 Demonstrates a High Response Rate as a Single-Agent with Acceptable Safety in Rituximab-Refractory, Relapsed Indolent or Transformed Non-Hodgkin's Lymphoma (NHL).

[2481] Selective Rapid B-Cell Depletion In Vivo by Pharmacologic IKK2 Inhibition.

[2482] Bendamustine/Mitoxantrone/Rituximab (BMR): A Very Effective and Well Tolerated Immuno-Chemotherapy for Relapsed and Refractory Indolent Lymphomas – Results of a Multicentre Phase-II-Study of the German Low Grade Lymphoma Study Group (GLSG).

[2483] Rituximab, Gemcitabine and Oxaliplatin (R-GEMOX): A Promising Regimen for Refractory/Relapsed B-Cell Lymphoma.

[2484] Combined Targeting of the Proteasome and Bcl-2 Sensitizes Human B-Cell Lymphoma and Multiple Myeloma to Cyclophosphamide in In Vitro and In Vivo Models of These Diseases.

[2485] Identification and Characterization of an ALK Inhibitor That Attenuates the Proliferation and Survival of Anaplastic Large Cell Lymphoma-Derived Cell Lines and ALK Dependent Cell Lines.

[2486] CALGB 59901: Results of a Phase II Study of 506U78 in CTCL and PTCL.

[2487] Phase 2 Multicenter Trial of Gallium Nitrate in Patients with Advanced Non-Hodgkin’s Lymphoma (NHL).

[2488] Treatment Response to Single Agent Sphingosomal Vincristine in Patients with Relapsed and/or Refractory Diffuse Aggressive Non-Hodgkin’s Lymphoma (NHL): Subgroup Analyses.

[2489] Preliminary Phase II Study Results of BBR2778 in Combination with Cyclophosphamide, Vincristine, and Prednisone in Patients with Relapsed Aggressive Non-Hodgkin's Lymphoma.

[2490] Antibody-Targeted Chemotherapy with Immunoconjugates of Calicheamicin: Differential Anti-Tumor Activity of Conjugated Calicheamicin Targeted to B-Cell Lymphoma Via B-Cell Lineage Specific Molecules CD19, CD20 and CD22.

[2491] Intravenous Forodesine (BCX-1777), a Novel Purine Nucleoside Phosphorylase (PNP) Inhibitor, Demonstrates Clinical Activity in Patients with Refractory Cutaneous T-Cell Lymphoma.

[2492] Phase I Dose Escalation Study of Flavopiridol in Combination with Fludarabine and Rituximab: Activity in Indolent B-Cell Lymphoproliferative Disorders and Mantle Cell Lymphoma.

[2493] Periocular MALT Lymphomas (Conjunctival/Orbital): Complete Responses with Antibiotic Therapy.

[2494] Phase II Study of Oxaliplatin in Patients with Relapsed or Refractory Non-Hodgkin’s Lymphoma: Final Results.

[2495] High Dose and Conventional Anthracycline Regimen for Adult Non-Hodgkin’s Primary Bone Lymphoma (PBL). A GOELAMS’s Trial.

[2496] AHOD00P1, a Pilot Study of Re-Induction Chemotherapy with Ifosfamide, and Vinorelbine (IV) in Children with Refractory/Relapsed Hodgkin Disease.

[2497] Leflunomide Inhibits Proliferation of Neoplastic B-Cell Lines and Induces Apoptosis in Primary CLL Cells.

[2498] A Novel N-Oxide Drug, AQ4N, Has In Vitro Activity in Lymphoma and Leukemia Cell Lines and Selectively Targets Lymphocytes and Lymphatic Tissues In Vivo.

[2499] Analysis of the Effect of the Novel Histone Deacetylase Inhibitor, Depsipeptide (FK228/FR901228) on Mantle Cell Lymphoma.

[2500] Sequential Topoisomerase I (topo I) and Topoisomerase II (topo II) Inhibitors in Relapsed/Refractory Aggressive NHL: Results of CALGB 59906, a Phase II Study of Doxorubicin and Topotecan. S

[2501] Sapphyrins Exhibit Tumor Selectivity and Efficacy in Animal Models of Hematologic Malignancies.

[2502] The Induction of Apoptosis in Lymphoma Cells by Methylseleninic Acid and Selenodiglutathione.

Radioimmunotherapy - Non Hodgkin's Lymphoma and T-cell Lymphoma

[2629] Yttrium 90 (90Y) Ibritumomab Tiuxetan (Zevalin®) Induces Long-Term Responses in Patients with Relapsed or Refractory Follicular Lymphoma (FL).

[2630] Tositumomab and Iodine I 131 Tositumomab (the BEXXAR® Therapeutic Regimen) Shows Efficacy in Elderly Patients (pts) with Relapsed/Refractory Low-Grade (LG), Follicular, and Transformed Non-Hodgkin’s Lymphoma (NHL).

[2631] Tositumomab and Iodine I 131 Tositumomab (The BEXXAR® Therapeutic Regimen) Produced Ongoing, Durable Remissions of More Than 5 Years in 9 Patients with Non-Hodgkin’s Lymphoma (NHL) in a Pivotal Study of Patients Refractory to Their Last Chemotherapy.

[2632] A Phase II Study of Yttrium 90 (90Y) Ibritumomab Tiuxetan (Zevalin®) for Treatment of Patients with Relapsed and Refractory Mantle Cell Lymphoma (MCL).

[2633] Efficacy and Safety of Yttrium 90 (90Y) Ibritumomab Tiuxetan (Zevalin®) Therapy with Rituximab Maintenance in Patients with Untreated Low-Grade Follicular Lymphoma.

[2634] Evaluation of Baseline Body-Weight Dosing of Yttrium 90 (90Y) Ibritumomab Tiuxetan (Zevalin®) Radioimmunotherapy in Patients with Relapsed or Refractory B-Cell Non-Hodgkin’s Lymphoma (NHL).

[2636] Phase I/II, Open-Label, Dose-Escalating Study of MDX-060 Administered Weekly for 4 Weeks in Subjects with Refractory/Relapsed CD30 Positive Lymphoma.

[2637] SGN-30 (Anti-CD30 Monoclonal Antibody) Is Active and Well Tolerated in Patients with Refractory or Recurrent Systemic Anaplastic Large Cell Lymphoma.

[2640] Combination Chemoimmunotherapy Using Alemtuzumab, Fludarabine, Cyclophosphamide, and Doxorubicin (Campath-FCD) Is an Effective First-Line Regimen in Peripheral T-Cell Lymphomas.

[2641] Interim Analysis of a Phase II Study of Denileukin Diftitox (Ontak) for Relapsed/Refractory T-Cell Non-Hodgkin’s Lymphoma.

[2642] Intermediate-Dose Interleukin-2 Demonstrates Activity in Patients with Relapsed or Refractory Cutaneous T-Cell Lymphoma.

[2643] Interferon Alpha-2B (IFN-a) Is an Effective Agent for the Treatment of Primary Cutaneous T- and B-Cell Lymphoma.

[2644] Results of a Phase II Trial of Oral Bexarotene Combined with Interferon Alfa-2b for Patients with Cutaneous T-Cell Lymphoma (CTCL).

[2645] Prolonged Severe Pancytopenia and Myelodysplastic Features Following Alemtuzumab Therapy in Patients with Cutaneous T-Cell Lymphomas.

[2646] Upregulation of the Chemokine Receptor CCR4 in Cutaneous T-Cell Lymphoma and Nodal T-Cell Lymphoma: Implications for Targeted Therapy

Chemotherapy and Rituximab combinations for B-Cell Non-Hodgkin's Lymphoma

[157] First Analysis of the Completed Mabthera International (MInT) Trial in Young Patients with Low-Risk Diffuse Large B-Cell Lymphoma (DLBCL): Addition of Rituximab to a CHOP-Like Regimen Significantly Improves Outcome of All Patients with the Identification of a Very Favorable Subgroup with IPI=O and No Bulky Disease.

[158] Effect of Adding Rituximab to Three Cycles of CHOP Plus Invoved-Field Radiotherapy for Limited-Stage Aggressive Diffuse B-Cell Lymphoma (SWOG-0014).

[159] Dose-Adjusted EPOCH-Rituximab Is Highly Effective in the GCB and ABC Subtypes of Untreated Diffuse Large B-Cell Lymphoma.

[160] Rituximab Added to αIFN+CHVP Improves the Outcome of Follicular Lymphoma Patients with a High Tumor Burden: First Analysis of the GELA-GOELAMS FL-2000 Randomized Trial in 359 Patients.

[161] The Addition of Rituximab to Combination Chemotherapy with CHOP Has a Long Lasting Impact on Subsequent Treatment in Remission in Follicular Lymhoma but Not in Mantle Cell Lymphoma: Results of Two Prospective Randomized Studies of the German Low Grade Lymphoma Study Group (GLSG).

[162] Combined Immuno-Chemotherapy (R-CHOP) Results in Significantly Superior Response Rates and Time to Treatment Failure in First Line Treatment of Patients with Lymphomplasmocytoid/ic Immunocytoma (LP-IC) - Results of a Prospective Randomized Trial of the German Low Grade Lymphoma Study Group (GLSG).

Clincial trials and drug approval

[265] FDA Policies Should Be Amended To Allow Pharmaceutical Manufacturers To Disseminate Information Regarding Potentially Fatal Toxicities That Occur with Off-Label Use of Oncology Agents: A Policy Recommendation Based on Review of Thalidomide-Associated Thromboembolism Cases by the RADAR Project.

[266] Accelerated FDA Approval of Drugs Used To Treat Hematologic Malignancies: Are Policy Changes Needed?

[267] Liposomal Cytarabine (DepoCyte™ Injection) Is Cost-Effective Compared with Standard Cytarabine for the Intrathecal Treatment of Patients with Lymphomatous Meningitis.

[268] Economic Evaluation of Bortezomib (VELCADE) for Relapsed and Refractory Multiple Myeloma.

[269] Entry Bias: Order of Patient Entry Influences Outcome in Trials of Allogeneic Transplant for Renal Cell Carcinoma.

[270] Creating a National Cohort of Myeloproliferative Disorders Using the Internet: A Feasibility Study.

Graft Versus Host Disease

[421] Association of IL-10 and IL-10 Receptor Gene Polymorphisms and Graft-Versus-Host Disease Following Hematopoietic Cell Transplantation.

[422] IL-10 Promoter Gene Polymorphism Associated with the Occurrence of Chronic GVHD and Its Clinical Course during Systemic Immunosuppressive Treatment for Chronic GVHD after Allogeneic Peripheral Blood Stem Cell Transplantation.

[423] Prognostic Relevance of “Early-Onset” Graft-Versus-Host Disease Following Nonmyeloablative Hematopoietic Cell Transplantation.

[424] NOD2/CARD15 Mutations Associate with Transplant Related Mortality and GvHD in HLA-Identical Sibling Transplants: Detailed Analysis of Single SNPs in 211 Recipient/Donor Pairs.

[425] Mutations Innate Immune System NOD/CARD15 Gene and Toll-Like-Receptor-4 Gene Are Associated with Increased Risk for Severe Acute GVHD in Patients Who Underwent Allogeneic Transplantation.

[426] Selective Depletion of Alloreacting CD25+ Cells from Stem Cell Allografts Can Reduce Acute Graft-Versus-Host Disease Following Matched Related Donor Transplantation.

Follicular Lymphoma Therapy

[583] New Treatment Options Have Changed the Natural History of Follicular Lymphoma.

[584] Results of a Prospective Randomised Open Label Phase III Study Comparing Rituximab Plus Mitoxantrone, Chlorambucile, Prednisolone Chemotherapy (R-MCP) Versus MCP Alone in Untreated Advanced Indolent Non-Hodgkin's Lymphoma (NHL) and Mantle-Cell-Lymphoma (MCL).

[585] Single 4-Dose Rituximab Treatment for Low-Tumor Burden Follicular Lymphoma (FL): Survival Analyses with a Follow-Up (F/Up) of at Least 5 Years.

[586] Chimeric Anti-CD20 Monoclonal Antibody (Rituximab; Mabtheraâ) in Remission Induction and Maintenance Treatment of Relapsed /Resistant Follicular Non-Hodgkin’s Lymphoma: A Phase III Randomized Intergroup Clinical Trial.

[587] Id/KLH Vaccine (FavId™) Following Treatment with Rituximab: An Analysis of Response Rate Improvement (RRI) and Time-to-Progression (TTP) in Follicular Lymphoma (FL).

[588] Factors Prognostic for Response and Event Free Survival and Treatment Related Toxicity in 306 Patients with Follicular or Mantle Cell Lymphoma Randomized to Single Agent Rituximab Given at the Standard or at a Prolonged Schedule.

[589] Fcγ Receptor Polymorphisms Do Not Influence Progression Free Survival (PFS) of Follicular NHL Pateints Treated with Chop Followed by Rituximab (SWOG 9800).

[590] Evidence for Fcγ Receptor IIIA-Independent Rituximab Effector Mechanisms in Patients with Follicular Lymphoma Treated with Combined Immuno-Chemotherapy.

Lymphoma Chemotherapy

[607] A Multicenter Experience with Single Agent Bortezomib in Non-Hodgkin’s Lymphoma Reveals Marked Differences in Sub-Type Sensitivity to Proteasome Inhibition.

[608] Phase II Trial of Bortezomib in Mantle Cell Lymphoma.

[609] A Phase I/II Study of Arginine Butyrate and Ganciclovir in Patients with Epstein-Barr Virus-Associated Lymphoid Malignancies.

[610] Repetitive High-Dose Therapy with Dose Escalated CHOP + Etoposide Followed by Autologous Stem Cell Transplantation (Mega-CHOEP) in Younger Patients with Primary Diagnosis of Aggressive NHL and Elevated LDH at Diagnosis: Final Analysis.

[611] CHOP Improves Response Rates but Not Overall Survival in Follicular and Mantle Cell Lymphoma (MCL)– Results of a Randomized Trial of the German Low Grade Lymphoma Study Group (GLSG).

[612] Salvage Therapy of Progressive and Recurrent Hodgkin’s Disease: Results from a Multicenter Study of the Pediatric DAL/GPOH HD-Study Group.

[613] Patients with Follicular Lymphoma, Grade 3, Have a Prolonged Relapse-Free Survival Following Aggressive Combination Chemotherapy.

[614] Primary Mediastinal Large B Cell Lymphoma: Elucidating Optimal Therapy and Prognostic Factors; an Analysis in 141 Consecutive Patients Treated at Memorial Sloan Kettering from 1980-1999.

Allogeneic Mismatched and Unrelated Transplantation

[2750] Hematopoietic Stem-Cell Transplantation from Unrelated Donors in Elderly Patients (> 55 Years): Older Age Is No Longer a Contraindication When Using Reduced Intensity Conditioning.

[2751] Non-Ablative or Reduced Intensity Conditioning Regimens with Volunteer Unrelated Donor Progenitor Cell Transplantation.

[2752] A Retrospective Study of Patients Treated with Imatinib Mesylate Prior to Allogeneic Hematopoietic Stem Cell Transplant.

[2753] Higher Doses of Transplanted CD34+, CD3+ and CD8+ Cells Are Associated with Better Donor T-Cell Chimerism and Less Graft Rejection, but Not with GVHD after Nonmyeloablative Conditioning for Unrelated Hematopoietic Cell Transplantation.

[2754] Long-Term Follow-Up of 5,930 Unrelated Volunteers Donating Bone Marrow or Peripheral Blood Stem Cells.

[2757] Is a Younger 10-Allele-Matched Unrelated Donor (MUD) Better Than an Older 6-Antigen-Matched Sibling Donor (MSD) for Allogeneic HSCT?

[2758] Impact of HLA Mismatch on the Incidence of Acute GVHD and Rejection after Reduced-Intensity Conditioning Hematopoietic Stem Cell Transplantation (RICT).

[2759] Non-Myeloablative Allogeneic Transplantation in Patients with Relapsed or Refractory Multiple Myeloma. Session

[2761] Improved Long Term Survival with Minimal GVHD after Myeloablative Unrelated Donor Stem Cell Transplantation Using In Vitro and In Vivo T Cell Depletion with CAMPATH-1H.

[2762] Outcomes Analysis of Patients Surviving ≥2 Years after Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation (AHSCT).

[2763] Reduced-Intensity Unrelated Cord Blood Transplantation (RICBT) for Adults with Hematological Diseases.

[2764] Long-Term Results of Allogeneic Hematopoietic Stem Cell Transplantation Using Unrelated or HLA Mismatched Family Donors for Acute and Chronic Lymphoid Malignancy.

Clinical results of Autologous Transplantation

[2921] Stem Cell Factor (SCF) for Hematopoietic Stem Cell (HSC) Mobilization: Results of the Randomized IFM 99-01 Trial.

[2922] Single-Dose Pegfilgrastim after Chemotherapy Is Highly Effective in Enhancing the Mobilization of Autologous CD34+ Peripheral Blood Stem Cells in Patients with Lymphoid Malignancies and Solid Tumors.

[2923] Ancestim (r-metHuSCF) in Combination with Filgrastim To Rescue Mobilization and Collection of Peripheral Blood Progenitor Cells for Autologous Transplantation. Compassionate Use in 372 Patients at 68 Sites in France (1998-2004).

[2925] A ”Single“ Dose of G-CSF after Autologous Stem Cell Transplantation in Patients with Malignant Lymphoma - Third Interim Analysis of Multicentre Randomized Trial Comparing Standard Schedule with Delayed Application and Placebo.

[2926] Evaluating the Clinical Efficacy of Increased Granulocyte Colony-Stimulating Factor (GCSF) in Patients Who Fail a Standard Dose Regimen during Peripheral Blood Stem Cell (PBSC) Collection.

[2927] Time Interval from Last Chemotherapy to Stem Cell Collection Correlates with Peripheral Blood Absolute Lymphocyte Count at Apheresis and Survival Post-Autologous Stem Cell Transplantation in Non-Hodgkin’s Lymphoma.

[2928] Autologous Stem Cell Transplantation (ASCT) as Consolidation Therapy for Patients with Low-Intermediate (LI) Risk Diffuse Large B-Cell Lymphoma (DLBCL) and Overexpression of bcl2 Protein. Results of the First Interim Analysis of the GELA Trial LNH98-B2.

Lymphoma Biology - Prognostic markers

[3250] Immunoglobulin G Fc Receptor Polymorphisms and Clinical Course in Follicular Lymphoma Patients.

[3252] Lymphocyte Count Persistence and Early Recovery Predicts Superior Survival and Is Independent of the International Prognostic Index in Patients Treated with CHOP Chemotherapy for Diffuse Large B Cell Lymphoma.

[3253] Transformed Lymphoma: Incidence and Long-Term Outcome.

[3254] Unmutated Immunoglobulin Heavy Chain Variable Region Genes and Disease Progression Post Splenectomy Are Poor Prognostic Factors in Splenic Marginal Zone Lymphoma.

[3255] FoxP3, a Key Molecule in CD4+CD25+ Regulatory T Cells, Express in Adult T Cell Leukemia/Lymphoma Cells and Relates to Clinicopathological Features.

[3256] The Peripheral Cannabinoid Receptor CB2 and CD40 Are Novel Biological Markers That Predict Outcome in Diffuse Large B-Cell Lymphoma of Elderly Patients.

[3257] T-Cells Present in Tumour Tissue May Affect the Outcome of Follicular Lymphoma.

[3258] PKC-beta 2 Protein Expression Predicts for Poor Response to Chemotherapy and Survival in Patients with Low Risk Diffuse Large B-Cell Lymphoma.

[3259] Lymphoma-Associated Macrophage (LAM) Content Is an Independent Predictor of Survival in Patients with Follicular Lymphoma (FL).

[3260] Pre-Transplantation FDG-PET Is the Best Predictor for Outcome in Relapsed Lymphoma Patients Treated with Autologous Stem Cell Transplantation.

[3261] A Predictive Model for Limited Stage Diffuse Large B-Cell Lymphoma (DLBCL): A Retrospective Analysis of 1,252 Cases Performed by the Intergruppo Italiano Linfomi (IIL).

[3262] The Percentage of Tumor-Infiltrating T Cells Is Not Correlated with Overall Survival in Follicular B-Cell Lymphomas.

[3263] Histologic Subtypes Do Not Confer Unique Outcomes in Early-Stage Lymphoma: Long-Term Follow-Up of SWOG 8736.

[3264] Primary Nasal NK/T Cell Lymphoma: Cytology and Level of the Antiapoptotic PI9 Protein Have Prognostic Relevance.

[3265] An IELSG International Survey of Primary Effusion Lymphoma (PEL).

[3266] c-Myc Amplification in Non Hodgkin's-Lymphomas with Burkitt-Like Features Is Associated with a Poor Prognosis.

[3267] Fas or Fas Ligand Expression Can Determine the Clinical Outcome of Germinal Center Type in Diffuse Large B Cell Lymphoma.

[3268] The Follicular Lymphoma International Prognostic Index (FLIPI) Is Superior to WHO/REAL Histological Grade for Identifying High-Risk Patients: A Retrospective Review of the MSKCC Experience in 260 Patients with Follicular Lymphoma.

[3269] A Circulating T Cell Clone in Early Mycosis Fungoides Is Not a Negative Prognostic Factor When the Disease Is Treated by a Combination of PUVA + Interferon α.

[3272] Analysis of Factors Involved in Malignant Progression of Anaplastic Large Cell Lymphoma Kinase (ALK) -Negative Anaplastic Large Cell Lymphoma.

[3273] HLA-DR Protein Status Predicts Survival in Patients with Diffuse Large B Cell Lymphoma (DLBCL) Treated with the MACOP-B Chemotherapy Regimen.

Lymphoma Therapy - New Biologic Agents

[3274] Chlamydia Psittaci-Eradicating Antibiotic Therapy as a Potential Therapeutic Strategy Against Marginal Zone B-Cell Lymphoma of the Ocular Adnexa.

[3276] LMP2-Cytotoxic T Lymphocyte Therapy for Relapsed EBV Positive Lymphoma.

[3277] Development of Effective Immunotherapy for B-Cell Non-Hodgkin’s Lymphoma with CD19-Specific Cytotoxic T Cells.

[3278] Antitumor Activity of Bortezomib (PS-341; Velcade) in a Phase II Study of Patients with Previously Untreated or Treated Waldenstrom’s Macroglobulinemia (WM).

[3279] A Fully Human Anti-CD40 Antagonistic Antibody, CHIR-12.12, Inhibit the Proliferation of Human B Cell Non-Hodgkin's Lymphoma.

[3280] Cyclophosphamide Induced CD11b+ Cells Can Inhibit Anti-CD40 Monoclonal Antibody (mAb) Therapy of B-Cell Lymphoma.

[3281] Antagonist Anti-CD40 Monoclonal Antibody, CHIR-12.12, Inhibits Growth of a Rituximab-Resistant NHL Xenograft Model and Achieves Synergistic Activity When Combined with Ineffective Rituximab.

[3284] Phase II Study of Thalidomide in Escalating Doses for Follicular (F-NHL) and Small Lymphocytic Lymphoma (Sll): CALGB Study 50002.

[3285] In Vitro and In Vivo Anti-Lymphoma Activity of the Anti-HLA-DR Monoclonal Antibody 1D09C3.

[3286] GCS-100, a Galectin 3 Antagonist, Is a Novel Caspase-9 Apoptosis Activating Agent for the Treatment of Indolent B-Cell Malignancies.

[3287] In Vitro and In Vivo Targeting and Therapy of an Antibody-Drug Conjugate (IMMU-110) in B-Cell Malignancies.

[3290] Antibodies to TRAIL Receptors TRAIL-R1 and R2 Induce Apoptosis in Non-Hodgkin’s Lymphoma Cells.

[3291] The Geldanamycin Analogue Heat Shock Protein 90 (HSP90) Inhibitor 17-AAG in Lymphomas: Molecular Mechanisms of 17-AAG-Induced Cell Death in Hodgkin Disease and Non- Hodgkin Lymphoma Cell Lines.

[3292] Fc-Gamma Receptor IIIa and Interferon-Gamma SNPs Do Not Predict Responsiveness of Follicular Lymphoma to Galiximab (Anti-CD80 Antibody).

[3294] Mantle Cell and Follicular Lymphoma Samples Demonstrate Differing Sensitivity to Bortezomib in a Primary Culture System.

[3295] The Human Anti-CD30 Antibody 5F11 Activates NF-kB and Sensitizes Lymphoma Cells to Bortezomib Induced Apoptosis.

[3296] Efficacy of Darbepoetin Alfa in the Treatment of Chemotherapy-Induced Anemia in Non-Hodgkin’s Lymphoma.

Lymphomas - Chemotherapy and Management of Treatment Complications

[3297] Outcome with the Hyper-CVAD and Rituximab Regimen in Burkitt (BL) and Burkitt-Like (BLL) Leukemia/Lymphoma.

[3298] Oral Melphalan, Cyclophosfamide and Prednisone (MCP) in 72 Newly Diagnosed Waldenström’s Macroglobulinemia Patients: Results and Costs Analysis.

[3299] FDG PET Scan Alone Better Predicts Progression Free Survival at 2 Years Compared to CT Imaging in Aggressive Histology Non-Hodgkin's Lymphoma Following Initial Anthracycline-Based Chemotherapy.

[3300] Primary Central Nervous System Lymphoma in Children: A Report of 12 Cases.

[3301] Primary Mediastinal Large B-Cell Lymphoma: Long Term Results with an Alternating Chemotherapy Regimen Based on High-Dose Methotrexate.

[3302] Outcome of Patients with Primary Mediastinal Large B-Cell Non-Hodgkin's Lymphomas: A Single Institution Analysis from 1996-2004.

[3303] Treatment Outcome of Aggressive Lymphoma with CyclOBEAP (CHOP-Like + Etoposide and Bleomycin): Results of Multicenter Trial.

[3304] Polychemotherapy in Patients with Primary CNS Lymphoma.

[3305] Randomized Multicenter Trial of Cladribine Alone (C) or in Combination with Cyclophosphamide (CC), and COP in Previously Untreated Low Grade B-Cell Non-Hodgkin Lymphoma Patients: The First Interim Analysis.

[3306] CHOP Followed by Radiotherapy for Localized Aggressive Primary Gastric Lymphoma: Results of a Multi Center Phase II Study.

[3307] Efficacy and Safety of CHOP-14 in Elderly Patients with Very Poor Risk Diffuse Large B-Cell Lymphoma.

[3308] CODOX-M/IVAC (NCI 89-C-41) for Children and Adolescents with Small Non-Cleaved and Large B-Cell Lymphomas. A 14 Years Monocentric Experience.

[3309] Patterns of Growth Factor (GF) Usage and Febrile Neutropenia (FN) among Older Patients (pts) with Diffuse Large B-Cell Lymphoma (DLBCL) Treated with CHOP or R-CHOP: An Intergroup Experience (CALGB 9793, ECOG-SWOG 4494).

[3310] Thrombopoietin Protects Against Cardiotoxicity Induced by Doxorubicin.

[3311] Pegfilgrastim Supports Delivery of CHOP-R Chemotherapy Administered Every 14 Days: A Randomised Phase II Study.

[3313] A Comparison of Acute and Delayed Infection Rates among Patients with Indolent Lymphoid Malignancies Receiving Fludarabine(F) and Cyclophosphamide(C) with or without Rituximab(R).

[3314] Reduced Relative Dose Intensity (RDI) in Patients with Aggressive Non-Hodgkin’s Lymphoma (NHL).

[3315] Role of Anemia in Survival of Elderly Aggressive Non-Hodgkin’s Lymphoma Patients Following Chemotherapy.

[3316] Respect of Average Relative Dose Intensity Correlates with Survival in Diffuse Large B Cell Lymphoma Patients Treated by CHOP: A National Retrospective Study (1995-2000). Session Type: Poster Session 586-III - 5:30 pm - Halls DE

Lymphoma - Therapy with Biologic Agents

[743] TLR9 Agonist Immunomodulator Treatment of Cutaneous T-Cell Lymphoma (CTCL) with CPG7909.

[744] Bexarotene-Induced T-Cell Immunomodulation and Response in CTCL

[747] Rituximab Given after High Dose Therapy and Autologous Stem Cell Transplantation Induces Durable Clearance of Minimal Residual Disease in about Half of the Patients with Follicular Non Hodgkin's Lymphoma: 36 Months Results of a Multicenter Open Label Phase II Trial (M39012 Trial).

[748] The Number of CD25+ Tumor-Infiltrating Cells May Predict Clinical Response to Rituximab in Follicular Lymphoma Patients.

[750] Tumor Targeting, Dosimetry and Clinical Response Data for Lymphorad-131 (LR131; Iodine I-131 Labeled B-Lymphocyte Stimulator) in Patients with Relapsed/Refractory Non-Hodgkin’s Lymphoma.

Reduced Intensity Conditioning

[808] Reduced-Intensity Conditioning (RIC) Followed by Allogeneic Transplantation in Relapsed Lymphomas: Evidence for Graft-Versus-Lymphoma Effect in Low and High Grade Histologies, but Not in Hodgkin Disease.

[809] Allogeneic Hematopoietic Cell Transplantation after Fludarabine and 2 Gy Total Body Irradiation for Relapsed and Refractory Mantle Cell Lymphoma.

Strategies to Improve Allogeneic Mismatched and Unrelated Transplantation

[823] Unrelated Single Cord Blood Transplant Supported by Co-Infusion of a Low Number of Mobilized Peripheral Blood Highly Purified CD34+ Cells from a Third Party Donor after Low Toxicity Myeloablative Conditioning. A Strategy That Makes Cord Blood Transplant Feasible for Most Patients. (An “Allostem” Study).

[825] Non-Myeloablative Umbilical Cord Blood Transplantation (UCBT): Low Transplant-Related Mortality in 59 High-Risk Adults.

[826] Double Unit Myeloablative Umbilical Cord Blood (UCB) Transplantation in Adults & Adolescents: High Incidence of Engraftment and Low Transplant-Related Mortality